ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse - PubMed (original) (raw)
ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse
Camille Fos et al. J Immunol. 2008.
Abstract
ICOS ligation in concert with TCR stimulation results in strong PI3K activation in T lymphocytes. The ICOS cytoplasmic tail contains an YMFM motif that binds the p85alpha subunit of class IA PI3K, similar to the YMNM motif of CD28, suggesting a redundant function of the two receptors in PI3K signaling. However, ICOS costimulation shows greater PI3K activity than CD28 in T cells. We show in this report that ICOS expression in activated T cells triggers the participation of p50alpha, one of the regulatory subunits of class IA PI3Ks. Using different T-APC cell conjugate systems, we report that p50alpha accumulates at the immunological synapse in activated but not in resting T cells. Our results demonstrate that ICOS membrane expression is involved in this process and that p50alpha plasma membrane accumulation requires a functional YMFM Src homology 2 domain-binding motif in ICOS. We also show that ICOS triggering with its ligand, ICOSL, induces the recruitment of p50alpha at the synapse of T cell/APC conjugates. In association with the p110 catalytic subunit, p50alpha is known to carry a stronger lipid kinase activity compared with p85alpha. Accordingly, we observed that ICOS engagement results in a stronger activation of PI3K. Together, these findings provide evidence that p50alpha is likely a determining factor in ICOS-mediated PI3K activity in T cells. These results also suggest that a differential recruitment and activity of class IA PI3K subunits represents a novel mechanism in the control of PI3K signaling by costimulatory molecules.
Similar articles
- A single amino acid alteration in cytoplasmic domain determines IL-2 promoter activation by ligation of CD28 but not inducible costimulator (ICOS).
Harada Y, Ohgai D, Watanabe R, Okano K, Koiwai O, Tanabe K, Toma H, Altman A, Abe R. Harada Y, et al. J Exp Med. 2003 Jan 20;197(2):257-62. doi: 10.1084/jem.20021305. J Exp Med. 2003. PMID: 12538664 Free PMC article. - Grb2 and Gads exhibit different interactions with CD28 and play distinct roles in CD28-mediated costimulation.
Watanabe R, Harada Y, Takeda K, Takahashi J, Ohnuki K, Ogawa S, Ohgai D, Kaibara N, Koiwai O, Tanabe K, Toma H, Sugamura K, Abe R. Watanabe R, et al. J Immunol. 2006 Jul 15;177(2):1085-91. doi: 10.4049/jimmunol.177.2.1085. J Immunol. 2006. PMID: 16818765 - The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency.
Yong PF, Salzer U, Grimbacher B. Yong PF, et al. Immunol Rev. 2009 May;229(1):101-13. doi: 10.1111/j.1600-065X.2009.00764.x. Immunol Rev. 2009. PMID: 19426217 Review. - Activation and inhibition of lymphocytes by costimulation.
Frauwirth KA, Thompson CB. Frauwirth KA, et al. J Clin Invest. 2002 Feb;109(3):295-9. doi: 10.1172/JCI14941. J Clin Invest. 2002. PMID: 11827987 Free PMC article. Review. No abstract available.
Cited by
- ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis.
Cao L, Peng H, Chen Y, Xia B, Zeng T, Guo J, Yu F, Ye H, Zhang H, Chen X. Cao L, et al. J Immunother Cancer. 2024 Nov 11;12(11):e010028. doi: 10.1136/jitc-2024-010028. J Immunother Cancer. 2024. PMID: 39532433 Free PMC article. - Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, Lu Y, Xue J. Yin N, et al. Signal Transduct Target Ther. 2024 May 22;9(1):126. doi: 10.1038/s41392-024-01826-z. Signal Transduct Target Ther. 2024. PMID: 38773064 Free PMC article. Review. - ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.
Sharma N, Fan X, Atolagbe OT, Ge Z, Dao KN, Sharma P, Allison JP. Sharma N, et al. J Exp Med. 2024 Apr 1;221(4):e20231263. doi: 10.1084/jem.20231263. Epub 2024 Mar 22. J Exp Med. 2024. PMID: 38517331 Free PMC article. - Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell development.
Kim T, Martínez-Bonet M, Wang Q, Hackert N, Sparks JA, Baglaenko Y, Koh B, Darbousset R, Laza-Briviesca R, Chen X, Aguiar VRC, Chiu DJ, Westra HJ, Gutierrez-Arcelus M, Weirauch MT, Raychaudhuri S, Rao DA, Nigrovic PA. Kim T, et al. Nat Commun. 2024 Mar 9;15(1):2150. doi: 10.1038/s41467-024-46457-8. Nat Commun. 2024. PMID: 38459032 Free PMC article. - A systems and computational biology perspective on advancing CAR therapy.
Tserunyan V, Finley SD. Tserunyan V, et al. Semin Cancer Biol. 2023 Sep;94:34-49. doi: 10.1016/j.semcancer.2023.05.009. Epub 2023 May 30. Semin Cancer Biol. 2023. PMID: 37263529 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous